Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Obrixtamig is an investigational bispecific DLL3 engager that targets DLL3-expressing cancer cells in SCLC and NECs. Credit: CI Photos / Shutterstock.com.